Just like clockwork UltimateStockAlerts (google them) delivers winning picks. They sent me one earlier in the morning and I’m up 27% already
Aeterna Zentaris Announces Formal Implementation of its Sales Force In Support of Selling ASCEND's EstroGel(R)Monday 10/27/2014 07:30 AM ET - PR Newswire via Dow Jones News
QUÉBEC CITY, Oct. 27, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the formal implementation of its own full-time U.S. sales force with field selling of ASCEND Therapeutics US LLC(') s ("ASCEND"), EstroGel(R) , scheduled to start the week of November 17, 2014. EstroGel(R) is the leading non-patch transdermal brand of estrogen replacement therapy commercialized in the U.S. The selling of EstroGel(R) by Aeterna Zentaris is part of the strategic co-promotion services agreement signed last August with ASCEND which stipulates that Aeterna Zentaris will market this product, in specific U.S. territories. For its part, ASCEND would market, in specific U.S. territories, Aeterna Zentaris' product, Macrilen(TM), for use in the evaluation of adult growth-hormone deficiency ("AGHD"). A New Drug Application ("NDA") for Macrilen is currently under review by the FDA, with a Prescription Drug User Fee Act ("PDUFA") date of November 5, 2014. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.
Sentiment: Strong Buy
will you still be short when it hits 2.20 for no reason on no news? that is walls st. none of it needs to make any sense. just look at PBR this morning 10.82 election fun
Before missing its primary endpoint in Valor, I wrote here about the distinct weaknesses of the drug and the associated high risk of the trial. I am not a fan. Sapacitabine is where my money is (CYCC). Cyclacel's oral regimen will take elderly AML and RMDS by storm ( note SNSS and CYCC address different AML populations). SNSS has missed top line and it's market cap is still priced above CYCC, a superior company with a superior drug and a larger addressable market. Can SNSS recover? Maybe. They need to get the bar lowered in the EU as was the case with Dacogen. However, the case is not the same. When Dacogen was considered in the EU for AML, it was already approved for MDS and being routinely used by oncologists off label for AML. So it in essence had already become the defacto standard for AML. If the EU continues to lower the bar for AML, the field could become crowded and discourage new drug investment in AML. I think the marginal improvement offered by SNSS will be a tough sell.
as it's been a loser for lots of years but no any progress, only burning investors' money.